Literature DB >> 28387659

Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma.

Glenn J Hanna1, Vishwajith Sridharan2, Danielle N Margalit3, Stephanie K La Follette3, Nicole G Chau1, Guilherme Rabinowits1, Jochen H Lorch1, Robert I Haddad1, Roy B Tishler3, Karen S Anderson4, Jonathan D Schoenfeld3.   

Abstract

BACKGROUND: HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) is increasing in incidence. Laboratory assays that identify virally-mediated disease and predict HPV clearance in OPSCC may have important prognostic implications.
OBJECTIVE: Here we investigated serum, salivary HPV16 early (E) antibodies before and after definitive chemoradiotherapy (CRT) in patients with locoregionally advanced OPSCC.
METHODS: We prospectively measured salivary, serum samples at the beginning of and 6-7 weeks following the completion of CRT in 44 patients. IgG antibodies targeting N- and C-terminal fragments of E2 (NE2, CE2), E6 and E7 were measured by programmable enzyme-linked immunosorbent assay.
RESULTS: We observed serum antibodies directed against HPV-associated E proteins in patients with HPV-associated OPSCC. E7 directed antibodies were detected in saliva in the majority of patients, and were associated with HPV status (p= 0.03). When analyzed longitudinally, median salivary E7 antibody levels decreased significantly post-treatment (p= 0.007).
CONCLUSIONS: Our results demonstrate the feasibility of measuring HPV16 E antibodies in saliva and serum. E7 antibodies, in particular, are more detectable in saliva as compared with other E protein antibodies. Measuring E7 salivary antibody levels at various time points may have utility in understanding HPV clearance and should be explored for their ability to predict the risk of recurrence.

Entities:  

Keywords:  HPV; antibodies; oropharyngeal cancer; saliva

Mesh:

Substances:

Year:  2017        PMID: 28387659     DOI: 10.3233/CBM-160071

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  9 in total

1.  Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab.

Authors:  M Hardy-Werbin; O Arpí; A Taus; P Rocha; D Joseph-Pietras; L Nolan; S Danson; R Griffiths; M Lopez-Botet; A Rovira; J Albanell; C H Ottensmeier; E Arriola
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

2.  Rational genomic optimization of DNA detection for human papillomavirus type 16 in head and neck squamous cell carcinoma.

Authors:  Yuki Saito; Alexander V Favorov; Michael Forman; Shuling Ren; Akihiro Sakai; Takahito Fukusumi; Chao Liu; Sayed Sadat; Mizuo Ando; Guorong Xu; Zubair Khan; John Pang; Alex Valsamakis; Kathleen M Fisch; Joseph A Califano
Journal:  Head Neck       Date:  2019-12-18       Impact factor: 3.147

3.  Cell-Free HPV DNA Provides an Accurate and Rapid Diagnosis of HPV-Associated Head and Neck Cancer.

Authors:  Giulia Siravegna; Connor J O'Boyle; Jeremy D Richmon; Daniel L Faden; Shohreh Varmeh; Natalia Queenan; Alexa Michel; Jarrod Stein; Julia Thierauf; Peter M Sadow; William C Faquin; Simon K Perry; Adam Z Bard; Wei Wang; Daniel G Deschler; Kevin S Emerick; Mark A Varvares; Jong C Park; John R Clark; Annie W Chan; Vanessa Carlota Andreu Arasa; Osamu Sakai; Jochen Lennerz; Ryan B Corcoran; Lori J Wirth; Derrick T Lin; A John Iafrate
Journal:  Clin Cancer Res       Date:  2022-02-15       Impact factor: 13.801

4.  A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer.

Authors:  Yasmin Hasan; Larissa Furtado; Ana Tergas; Nita Lee; Rebecca Brooks; Anne McCall; Daniel Golden; Shruti Jolly; Gini Fleming; Matthew Morrow; Kimberly Kraynyak; Albert Sylvester; Fauzia Arif; Matt Levin; David Schwartz; Jean Boyer; Jeffrey Skolnik; Mark Esser; Rakesh Kumar; Mark Bagarazzi; Ralph Weichselbaum; Michael Spiotto
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-03-07       Impact factor: 7.038

5.  Detection of Circulating HPV16 DNA as a Biomarker for Cervical Cancer by a Bead-Based HPV Genotyping Assay.

Authors:  Luisa Galati; Jean-Damien Combes; Florence Le Calvez-Kelm; Sandrine McKay-Chopin; Nathalie Forey; Mathis Ratel; James McKay; Tim Waterboer; Lea Schroeder; Gary Clifford; Massimo Tommasino; Tarik Gheit
Journal:  Microbiol Spectr       Date:  2022-02-28

Review 6.  Oral manifestations of human papillomavirus infections.

Authors:  Stina Syrjänen
Journal:  Eur J Oral Sci       Date:  2018-10       Impact factor: 2.612

7.  Post-Treatment HPV Surface Brushings and Risk of Relapse in Oropharyngeal Carcinoma.

Authors:  Barbara Kofler; Wegene Borena; Jozsef Dudas; Veronika Innerhofer; Daniel Dejaco; Teresa B Steinbichler; Gerlig Widmann; Dorothee von Laer; Herbert Riechelmann
Journal:  Cancers (Basel)       Date:  2020-04-25       Impact factor: 6.639

Review 8.  Immunodiagnosis and Immunotherapeutics Based on Human Papillomavirus for HPV-Induced Cancers.

Authors:  Zhen Dong; Renjian Hu; Yan Du; Li Tan; Lin Li; Juan Du; Longchang Bai; Yingkang Ma; Hongjuan Cui
Journal:  Front Immunol       Date:  2021-01-08       Impact factor: 7.561

9.  Current perspectives on recurrent HPV-mediated oropharyngeal cancer.

Authors:  Theresa Guo; Stephen Y Kang; Ezra E W Cohen
Journal:  Front Oncol       Date:  2022-08-18       Impact factor: 5.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.